Aclaris Therapeutics Announces $80 Million Private Placement

Core Viewpoint - Aclaris Therapeutics, Inc. has announced a private placement of 35,555,555 shares of common stock at a price of $2.25 per share, aiming to raise approximately$80.0 million for research and development and general corporate purposes [1][2]. Group 1: Private Placement Details - The private placement is expected to close on or about November 19, 2024, pending customary closing conditions [1]. - Vivo Capital led the private placement, with participation from various investors including Forge Life Science Partners, Rock Springs Capital, RA Capital Management, Adage Capital Partners LP, Decheng Capital, Logos Capital, and Samsara BioCapital [2]. - The net proceeds will primarily fund the research and development of Aclaris' pipeline and support general corporate needs [2]. Group 2: Securities Information - The securities issued in the private placement have not been registered under the Securities Act of 1933, meaning they cannot be offered or sold in the U.S. without an effective registration statement or applicable exemption [3]. - A registration rights agreement has been established, obligating the company to file a registration statement with the SEC for the resale of the shares sold in the private placement [3]. Group 3: Company Overview - Aclaris Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, addressing unmet treatment needs [5]. - The company has a multi-stage portfolio of drug candidates supported by a robust research and development engine that explores protein kinase regulation [5].